Anlon Healthcare Acquires Majority Stake in Apiqo Organics for Rs 5.40 Crore

Anlon Healthcare Limited has announced a strategic move to strengthen its position in the pharmaceutical intermediates market. The company has entered into a Share Purchase Agreement (SPA) to acquire a controlling stake in Apiqo Organics Private Limited, a move that aims to enhance its vertical integration and manufacturing capabilities.

Key Acquisition Details

Aspect	Details
Target Company	Apiqo Organics Private Limited
Stake Acquired	67.48%
Acquisition Cost	Rs 5.40 crore
Shares Acquired	55,33,500 equity shares
Price per Share	Rs 9.76

Strategic Implications

The acquisition of Apiqo Organics is expected to bring several strategic benefits to Anlon Healthcare:

Vertical Integration: The move aims to enhance Anlon's vertical integration, potentially improving its supply chain efficiency and cost structure.
Manufacturing Capacity: The deal is set to add an additional 700-800 MT of annual manufacturing capacity for advanced pharmaceutical intermediates to Anlon's portfolio.
Supply Security: By acquiring Apiqo, Anlon seeks to secure a critical supply of high-quality intermediates, which could lead to more reliable production processes.
Market Position: The acquisition is expected to strengthen Anlon's position as a more agile, cost-competitive, and reliable partner for both innovator and generic pharmaceutical companies worldwide.

About Apiqo Organics

Apiqo Organics Private Limited, formerly known as M/s Apple Life Science, is engaged in manufacturing pharmaceutical intermediates, industrial and fine chemicals, and inorganic chemicals. The company was incorporated on December 1, 2025, following its conversion from a partnership firm to a private limited company.

Financial Snapshot of Apiqo Organics

Period	Turnover
As of March 31, 2025	Rs 977.78 Lakh
As of October 31, 2025	Rs 3,887.41 Lakh

Transaction Timeline

The acquisition is subject to customary closing conditions as outlined in the SPA. It is expected to be completed within three months from the date of signing the agreement, or as mutually agreed upon by the parties involved.

Regulatory Compliance

This disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The strategic acquisition by Anlon Healthcare demonstrates the company's commitment to growth and its focus on strengthening its position in the pharmaceutical intermediates market. By securing a critical supply chain component and expanding its manufacturing capabilities, Anlon aims to better serve the global pharmaceutical industry's needs.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-5.00%	-1.12%	+16.62%	+71.61%	+71.61%	+71.61%

Anlon Healthcare Limited , a Gujarat-based pharmaceutical intermediates and APIs manufacturer, has released its Q2/H1 FY26 investor presentation, highlighting its expanding global presence and robust financial performance. The company, which operates across 15 countries, has demonstrated significant growth in its operations and financial metrics.

Operational Highlights

Anlon Healthcare boasts a manufacturing capacity of 400 MTPA, currently operating at an impressive 84.41% utilization rate. The company has strengthened its regulatory footprint by filing 21 Drug Master Files (DMFs) with global regulatory authorities, signaling its commitment to quality and compliance in the international pharmaceutical market.

Financial Performance

The company's financial results for Q2 and H1 FY26 showcase substantial year-on-year growth:

Particulars (In INR Cr)	Q2 FY25	Q2 FY26	Growth (%)	H1 FY25	H1 FY26	Growth (%)
Total Income	24.21	52.23	115.74%	62.11	85.53	37.71%
EBITDA	7.57	13.77	81.90%	14.55	20.01	37.53%
PAT	2.59	9.32	259.85%	6.36	12.86	102.20%
EPS (In INR)	0.41	2.22	441.46%	2.56	3.07	19.92%

The company has shown remarkable improvement across all key financial metrics, with Q2 FY26 showing particularly strong growth compared to the same quarter in the previous year.

Balance Sheet Strength

As of H1 FY26, Anlon Healthcare's balance sheet reflects a solid financial position:

Net Worth: INR 214.32 Cr
Total Assets: INR 309.48 Cr
Current Assets: INR 287.51 Cr

The company's improved financial standing is further evidenced by its reduced long-term borrowings, which decreased from INR 38.36 Cr in FY25 to INR 30.86 Cr in H1 FY26.

Market Position

Anlon Healthcare's stock performance on the BSE as of the presentation date:

Share Price: INR 146.00
Market Capitalization: INR 776.01 Cr
52-Week High/Low: INR 149.50 / INR 86.98

Strategic Initiatives

The company has outlined several strategic moves to enhance its market position:

Targeting 10-15 global DMF filings in the next 5 years to expand its regulatory footprint.
Focusing on cost management and operational efficiencies to drive profitability.
Entering the Industrial and Fine chemicals business, marking a diversification strategy.
Aiming to strengthen its balance sheet with a INR 5.00 Cr allocation.

Leadership Enhancement

Anlon Healthcare has recently bolstered its leadership team:

Anandbhai Natwerlal Katkoria joined as a Non-Executive Non-Independent Director in August 2024, bringing over 20 years of banking sector experience.
Kannepalli Krishna Murty, a Chartered Accountant with 25 years of experience, joined as a Non-Executive Independent Director in August 2024, enhancing the company's financial governance.

Anlon Healthcare's Q2/H1 FY26 investor presentation underscores the company's strong growth trajectory, operational efficiency, and strategic initiatives aimed at expanding its global presence in the pharmaceutical intermediates and APIs market. The company's focus on regulatory compliance, coupled with its robust financial performance, positions it well for continued growth in the competitive pharmaceutical sector.